Today: 10 June 2026
Marvell stock (MRVL) rises after Melius upgrade sets $135 target ahead of CES CEO chat
5 January 2026
2 mins read

Marvell stock (MRVL) rises after Melius upgrade sets $135 target ahead of CES CEO chat

New York, January 5, 2026, 14:40 (EST) — Regular session

  • MRVL up about 1.5% after opening sharply higher on an analyst upgrade
  • Melius lifted Marvell to “buy” and set a $135 price target, a report said
  • Investors eye CEO comments at CES on Jan. 6 and the U.S. jobs report on Jan. 9

Marvell Technology, Inc. shares rose on Monday after Melius Research upgraded the chipmaker, keeping the stock in positive territory after an early spike. The shares were up about 1.5% at $90.69 after opening at $93.08.

The call matters because Marvell sits in the middle of the market’s debate over how long AI-driven data-center spending can stay strong in 2026. The company’s exposure to custom silicon — chips designed to one customer’s specifications — makes its growth outlook especially sensitive to big cloud customers’ buildout pace and product timing.

Investors have a near-term catalyst on Tuesday, when CEO Matt Murphy is scheduled to speak at a JPMorgan CES fireside chat, the company’s investor relations calendar shows. The week also brings the U.S. December jobs report on Friday, and Marvell’s next earnings are expected on March 4, according to Zacks.

Melius analyst Ben Reitzes upgraded Marvell to “buy” from “hold” and set a $135 price target, Barron’s reported. “The lasting power of AI for investors is anyone’s guess,” Reitzes wrote, while pointing to Marvell as an alternative AI play alongside Intel. Barron’s

Marvell last month agreed to buy startup Celestial AI for $3.25 billion, a deal it said would strengthen its push into next-generation AI infrastructure and close in the first quarter of calendar 2026. Reuters reported the deal centers on silicon photonics, which uses light rather than electrical signals to move data and ease connectivity bottlenecks inside large AI systems.

At CES in Las Vegas this week, Marvell said it plans to demonstrate copper and optical interconnect products and its CXL lineup, aimed at meeting rising memory and bandwidth needs in AI servers. CXL, short for Compute Express Link, is a standard designed to help link processors and accelerators to shared memory in data centers.

Technicians say the tape still has work to do. Marvell remains roughly 29% below its 52-week high of $127.48, but it is trading above its 50-day moving average of about $87.60, a level often treated as a near-term support gauge.

The stock’s relative strength stood out in a mixed semiconductor session. The iShares Semiconductor ETF was higher, while Nvidia and Broadcom were down, underscoring how stock picking has started to matter again inside the AI complex.

But the upside case depends on hyperscaler spending staying intact and custom chip programs landing on schedule, an area where delays can quickly push revenue out by quarters. Rate-sensitive growth stocks can also swing sharply around macro data, keeping traders wary of headline risk.

What markets watch next is Murphy’s JPMorgan CES fireside chat on Jan. 6 for any fresh color on custom silicon demand and the Celestial AI timeline, followed by Marvell’s earnings update expected March 4.

Stock Market Today

  • Palantir Technologies (PLTR) Shares Seen Fairly Valued Amid Recent Decline
    June 10, 2026, 5:48 PM EDT. Palantir Technologies has seen its share price fall 13.2% over the past week and 21.3% year to date, following extraordinary gains in prior years. At $132.07 per share, Palantir trades slightly below its estimated intrinsic value of $145.11 based on a Discounted Cash Flow (DCF) analysis, suggesting a modest 9% discount. The company posted $2.69 billion in free cash flow over the past twelve months, with projections rising to $16.11 billion by 2030. Despite recent volatility tied to sentiment on artificial intelligence and software spending, Palantir remains fairly valued but not a clear bargain. Investors should monitor further market developments and valuation metrics to gauge future opportunities or risks.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Previous Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push
Next Story

3.5 million hit by University of Phoenix data breach as school rolls out “credit for prior learning” push

Go toTop